Disc Medicine (IRON) CLO Rahul Khara Buys $110K of Stock

Rahul Khara, the Chief Legal Officer at Disc Medicine, Inc. (NasdaqGM: IRON), recently bought 7,500 shares of the company on June 18, 2026. The purchase was made at an average price of $14.69 per share, totaling an investment of $110,175. This transaction was not part of a pre-planned trading program.

Insider Buying and Selling at Disc Medicine, Inc.

On the same day as Khara's purchase, several other insider transactions took place. Liam Ratcliffe and Nadim Ahmed also acquired shares, with Ratcliffe buying 6,212 shares and Ahmed purchasing 5,176 shares. Meanwhile, CEO John Quisel executed a planned sale of 34,000 shares at $70.22 per share, while also buying back the same amount at $9.86 per share.

Other Institutional Activity in Disc Medicine

Institutional investors have shown varied activity in Disc Medicine. FMR LLC increased its holdings by 136,672 shares, bringing its total to 5,586,894 shares valued at approximately $357.2 million. RA Capital Management boosted its position by 474,089 shares, resulting in 2,450,221 shares worth about $156.7 million, marking a 24% increase. Wellington Management Group added 217,102 shares, ending with 1,735,376 shares valued at $111 million, a 14.3% increase. On the other hand, BlackRock, Inc. slightly reduced its stake by 1,149 shares to a total of 2,273,831 shares valued at $145.4 million.

Disc Medicine, Inc. Stock Up 1.8%

Shares of Disc Medicine, Inc. traded near $70.80 on Wednesday. The company has a market capitalization of approximately $2.70 billion. Despite not being profitable, its forward P/E ratio is -9.33, indicating expectations of future losses. The stock's beta is 2.101, suggesting it's more volatile than the broader market. The 52-week range for the stock is $40.00 to $99.50, with a 50-day moving average of $68.55 and a 200-day moving average of $73.16. Disc Medicine maintains a strong liquidity position with a current ratio of 24.00 and a quick ratio of 23.45.

Analysts Set New Price Targets

Analysts remain optimistic about Disc Medicine's prospects. On June 16, 2026, Morgan Stanley maintained its 'buy' rating with a price target of $85.00. Other firms, such as Stifel, Cantor Fitzgerald, and BMO Capital, have also maintained 'buy' ratings, with targets ranging from $79.00 to $125.00. The consensus among analysts is a 'strong buy', with an average target price of $101.55 based on 11 opinions.

About Disc Medicine

Disc Medicine, Inc. is a healthcare company based in Watertown, Massachusetts. It focuses on discovering and developing treatments for serious blood-related diseases. The company's pipeline includes several clinical and preclinical candidates targeting red blood cell formation and iron regulation. Founded in 2017, Disc Medicine is led by CEO Dr. John D. Quisel and employs around 154 people.

Bottom Line

Insider buying by Rahul Khara and other executives at Disc Medicine, Inc. suggests confidence in the company's future. While the company isn't currently profitable, its innovative approach in the biotechnology sector keeps it on analysts' radars. It's important to note that insider transactions are disclosed after they occur and might not reflect current insider sentiment.